EC Number   |
|---|
    2.1.2.3 | - |
| 2.1.2.3 | ATIC complex crystallized in monoclinic space group P2(1), a = 56.48 A, b = 107.88 A, c = 103.86 A and beta = 91.2° |
| 2.1.2.3 | crystal structure analysis of human enzyme complexed with the sulfamido-bridged N-[(S)-(4-([(2-amino-4-hydroxy-quinazolin-6-yl)dihydroxy-lambda-4-sulfanyl]amino)phenyl)-hydroxymethyl]-L-glutamic acid at 2.55 A resolution, PDB ID 1P4R |
| 2.1.2.3 | crystallized in a binary complex with methotrexate, single crystal at 96 K to 2.3 A resolution, monoclinic crystals, space group P2(1), with unit-cell dimensions a = 65.17, B = 105.93, c= 103.47 A, beta = 108.27 degrees |
| 2.1.2.3 | crystallized in complex with its inhibitor 2-[5-hydroxy-3-methyl-1-(2-methyl-4-sulfophenyl)-1H-pyrazo]-4-sulfobenzoic acid |
| 2.1.2.3 | purified recombinant His-tagged enzyme free or in complex with substrate 5-aminoimidazole-4-carboxamide ribonucleotide, both with adventitiously active site-bound nucleotide inhibitor of the cyclohydrolase activity, X-ray diffraction structure determination and analysis at 2.5 A and 2.2 A resolution, respectively |
| 2.1.2.3 | purified recombinant His6-tagged PurH, without methylation of the 28 lysine residues, sitting drop vapour diffusion method, mixing of 0.001 ml of 56 mg/ml protein in 0.8 M sodium/potassium hydrogen phosphate, pH 7.5, with 0.001 ml of reservoir solution containing 0.1 M sodium acetate, pH 5.0, 1 M ammonium sulfate, 1 week to 1 month, X-ray diffraction structure determination and analysis at 3.05 A resolution |
| 2.1.2.3 | recombinant His-tag fusion protein crystallized by sitting drop vapor diffusion method in complex with its inhibitor beta-DADF |
| 2.1.2.3 | sitting drop vapor diffusion method, co-crystallized in the presence of substrate with BW1540 and BW2315 |
| 2.1.2.3 | the three-dimensional structure of TM1249 is determined to 1.88 A resolution by molecular replacement |
